Combined modality immunotherapy and chemotherapy: a new perspective
R Ramakrishnan, S Antonia, DI Gabrilovich - Cancer Immunology …, 2008 - Springer
R Ramakrishnan, S Antonia, DI Gabrilovich
Cancer Immunology, Immunotherapy, 2008•SpringerThe results of recent clinical trials have demonstrated that cancer vaccines continue to
struggle to achieve tangible clinical benefits as monotherapy. Tumor-induced abnormalities
in the immune system hamper anti-tumor T cell responses limiting the effectiveness of
cancer immunotherapy. Recently, evidence has been mounting to suggest that
immunotherapy has the possibility of achieving better success when used in combination
with conventional chemotherapy. In clinical trials, immune responses elicited by cancer …
struggle to achieve tangible clinical benefits as monotherapy. Tumor-induced abnormalities
in the immune system hamper anti-tumor T cell responses limiting the effectiveness of
cancer immunotherapy. Recently, evidence has been mounting to suggest that
immunotherapy has the possibility of achieving better success when used in combination
with conventional chemotherapy. In clinical trials, immune responses elicited by cancer …
Abstract
The results of recent clinical trials have demonstrated that cancer vaccines continue to struggle to achieve tangible clinical benefits as monotherapy. Tumor-induced abnormalities in the immune system hamper anti-tumor T cell responses limiting the effectiveness of cancer immunotherapy. Recently, evidence has been mounting to suggest that immunotherapy has the possibility of achieving better success when used in combination with conventional chemotherapy. In clinical trials, immune responses elicited by cancer vaccines appear to augment the effectiveness of subsequent conventional cancer therapies.
Springer